Print this page    •   Back to Web version of article

The Body Covers: The 12th International AIDS Conference

Poster Session 12279: Two-Year Durability of HIV-1 Viral Load Suppression in Patients Treated with Indinavir who Experience Virus Load Declines to <500 VRNA Copies/mL

Coverage provided by Michael Giordano, M.D.

June 29, 1998

As researchers learn more about the importance of bringing viral load as low as possible for as long as possible, data about the magnitude and duration of viral load responses becomes especially important. For patients on therapy that includes indinavir, emergence of resistance is generally slower in patients who get their viral load below 500 copies/mL. This study examined results in 106 patients from several early indinavir studies, including monotherapy studies, who got to below 500 copies by Week 24 of their studies, and who stayed there for at least 12 weeks. The study then looked for patients who "failed", or rose back above the limits of detection, and whose virus had mutations associated with indinavir resistance.

Not surprisingly, after 108 weeks, patients who started on monotherapy had a greater chance of treatment failure due to resistance than those who started on triple therapy with indinavir and AZT/3TC (20% vs. 12% respectively). This is consistent with other studies presented here that emphasize how criticial is is to begin combination antiretroviral therapy all at the same time, rather than adding new drugs to existing regimens, or adding one drug after other over time.




This article was provided by TheBodyPRO.com. Copyright Body Health Resources Corporation. All rights reserved.

You can find this article online by typing the following address into your Web browser:
http://www.thebody.com/content/art14663.html

Please Note: Knowledge about HIV changes rapidly. Note the date of this article's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this article.

General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your healthcare provider.